After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company. The antibody-focused biotech is breaking free from invoX Pharma, a U.K.-based subsidiary of Sino Biopharmaceutical, as announced in a LinkedIn post by F-star.  Source: Fierce Biotech 4/4/2025